Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Tozbikian, Gary ^a   Brogi, Edi ^a   Kadota, Kyuichi ^a   Catalano, Jeffrey ^a   Akram, Muzaffar ^a   Patil, Sujata ^a   Ho, Alice Y ^a   Reis Filho, Jorge S ^a   Weigelt, Britta ^a   Norton, Larry ^a   Adusumilli, Prasad S ^a   Wen, Hannah Yong ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KERATIN; MESOTHELIN; PROGESTERONE RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BASAL LIKE BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL SURFACE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIUM CELL; MIDDLE AGED; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; BREAST; METASTASIS; PATHOLOGY; SURVIVAL; TRIPLE NEGATIVE BREAST NEOPLASMS;

BREAST; FEMALE; GPI-LINKED PROTEINS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84918568011     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114900     Document Type: Article

References (55)

1. Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381.
2. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93: 136-140.
3. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, et al. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868.
4. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, et al. (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35: 357-366.
5. Glass JP, Parasher G, Arias-Pulido H, Donohue R, Prossnitz ER, et al. (2011) Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms. Int J Surg Pathol 19: 588-596.
6. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13: 1571-1575.
7. Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, et al. (2002) Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 1: 595-600.
8. Frierson HF Jr., Moskaluk CA, Powell SM, Zhang H, Cerilli LA, et al. (2003) Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34: 605-609.
9. Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, et al. (2012) Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 18: 2478-2489.
10. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, et al. (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279: 9190-9198.
11. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, et al. (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5: 50.
12. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q (2011) Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10: 106.
13. Bharadwaj U, Li M, Chen C, Yao Q (2008) Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res 6: 1755-1765.
14. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, et al. (2006) Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 15: 1014-1020.
15. Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, et al. (2012) Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 21: 482-486.
16. Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53.
17. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, et al. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106: 3360-3365.
18. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, et al. (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17: 4719-4730.
19. Kelly RJ, Sharon E, Pastan I, Hassan R (2012) Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 11: 517-525.
20. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, et al. (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16: 6132-6138.
21. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion antimesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15: 5274-5279.
22. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, et al. (2012) A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 18: 858-868.
23. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, et al. (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657.
24. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, et al. (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23: 123-133.
25. Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, et al. (2010) Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 34: 956-964.
26. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
27. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728.
28. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, et al. (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134.
29. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, et al. (2006) Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8: R66.
30. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, et al. (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110: 876-884.
31. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
32. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, et al. (2008) How basal are triple-negative breast cancers? Int J Cancer 123: 236-240.
33. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
34. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23.
35. Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16 Suppl 1: 61-70.
36. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
37. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, et al. (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32.
38. Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41: 40-47.
39. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
40. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
41. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, et al. (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15: 2302-2310.
42. Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16 Suppl 1: 1-11.
43. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, et al. (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271.
44. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, et al. (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134: 907-922.
45. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43.
46. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, et al. (2012) Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 133: 799-804.
47. Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, et al. (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12: 827-831.
48. Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, et al. (2011) Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 40: 1276-1282.
49. Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, et al. (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105: 195-199.
50. Shimizu A, Hirono S, Tani M, Kawai M, Okada K, et al. (2012) Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 103: 739-746.
51. Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, et al. (2012) A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 7: e40157.
52. Kawamata F, Kamachi H, Einama T, Homma S, Tahara M, et al. (2012) Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol 41: 2109-2118.
53. Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, et al. (2012) Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107: 137-142.
54. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, et al. (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13: 378-384.
55. Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, et al. (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20: 1020-1028.